GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Asenapine (Secuado), transdermal film

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Secuado - labeled renal guidance

Product / population
Asenapine (Secuado), transdermal film
Renal method
GFR/eGFR in mL/min as reported by the source
Source revision
DailyMed SPL version 13, posted Feb 03, 2025
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Secuado - product and source limitations

The source does not establish a dialysis dose. Verify that the order is for the asenapine transdermal system.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Secuado - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Asenapine (Secuado), transdermal film

Renal method: GFR/eGFR in mL/min as reported by the source
Source date: DailyMed SPL version 13, posted Feb 03, 2025
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment

The patch needs no renal dose change over the studied GFR range of 15-90 mL/min. The source does not establish a dialysis dose. Verify that the order is for the asenapine transdermal system.

RDM74-secuado-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=685eaf44-5944-4f38-afba-0a4fc0b3462b
Retrieved
2026-11-07
Renal-function method
GFR/eGFR in mL/min as reported by the source
Source date/version
DailyMed SPL version 13, posted Feb 03, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
45aad1df481a2753d3841c44a0c6ae274327312ba830dfc5840137652eca62ef

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-secuado&s1=RDM74-secuado-official&h1=0ce517f5653996be63bf5520f41e6dee473b10914ee9e58abdd23b74ce79fb13

Top